MULTIPLE MYELOMA

Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.

During a case-based roundtable event, Dan Vogl, MD, MSCE, discussed possible targeted therapies for a patient with relapsed/refractory multiple myeloma who had previously received several combination therapies.

Findings from an analysis of the KarMMa study in patients with multiple myeloma signal that certain baseline characteristics are predictive of response to chimeric antigen receptor T-cell therapy.

Results from the phase 2 CARITUDE-2 trial of ciltacabtagene autoleucel in patients with multiple myeloma signaled that a 1 infusion can achieve deep responses.

During a live virtual event, Douglas Sborov, MD, MS, discussed the possible treatment regimens for a patient with newly diagnosed multiple myeloma who is eligible for stem cell transplant.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Shaji Kumar reviews data from his BELLINI clinical trial studying venetoclax paired with bortezomib and dexamethasone for multiple myeloma treatment.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Jonathan Kaufman explains clinical trial data on the efficacy of dexamethasone with venetoclax for multiple myeloma treatment.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Shaji Kumar, MD, describes the mechanism of action of BCL-2 inhibitor venetoclax and clinical trial data on its efficacy in multiple myeloma.

In an interview, Paul G Richardson, MD, discussed the many changes seen in the multiple myeloma space over previous years and what is expected for the future.

Shaji Kumar, MD, discusses the current treatment options and unmet needs for patients with newly diagnosed multiple myeloma.

Paul G. Richardson, MD, discusses the latest regulatory movement in the multiple myeloma space.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

MARCH study in patients with relapsed/refractory multiple myeloma confirms the results of the STORM study and demonstrates positive overall response rates.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the role of BCL-2 family proteins in normal cells and in multiple myeloma-affected cells.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, provides an overview of multiple myeloma, including prevalence and risk populations.

The evolving landscape for treating multiple myeloma has seen significant improvement for patients, giving them better options. One of the key regimens added to this landscape is the use of a new quadruplet regimen.

During a live virtual event, Faith E. Davies, MD, discussed treatment options for a patient with multiple myeloma who relapsed after multiple lines of treatment including autologous stem cell transplant.

Treatment options have expanded widely for patients with multiple myeloma over the past several years, resulting in significantly improved outcomes for these patients.

During a Targeted Oncology case-based roundtable event, Sumit Madan, MD, discussed the case of a 55-year-old patient with multiple myeloma who was refractory to multiple lines of therapy.

Ajay Chari, MD, discusses new blood testing options for patients with multiple myeloma.

During a Targeted Oncology case-based roundtable event, Luciano J. Costa, MD, PhD, discussed various treatment regiments for a patient with newly diagnosed multiple myeloma.

Prerna Mewawalla, MD, looks back at a decade of advancements in the multiple myeloma space.

Jesus Berdeja, MD, discusses the safety profile observed with the newly approved chimeric antigen receptor T-cell therapy, ciltacabtagene autoleucel as observed in the phase 1/2 CARTITUDE-1 clincial trial.